Global Finance News
17 Apr 2026, 16:41
Abbott Laboratories reported first-quarter 2026 results in line with expectations, posting GAAP diluted earnings per share of $0.61 and adjusted EPS of $1.15, up 6% year-over-year, while total sales rose 7.8% on a reported basis.
A key highlight of the quarter was the completion of Abbott’s acquisition of Exact Sciences, positioning the company as a major player in the rapidly growing oncology diagnostics market and adding a new high-growth segment to its portfolio.
Abbott maintained a positive outlook for 2026, projecting full-year comparable sales growth of 6.5% to 7.5% and adjusted EPS of $5.38 to $5.58, including a modest dilution impact from the acquisition. The company also reported progress across its medical technology pipeline, including advancements in cardiovascular devices and diabetes management solutions, supporting expectations for accelerating growth through the year.
PRNewswire
A key highlight of the quarter was the completion of Abbott’s acquisition of Exact Sciences, positioning the company as a major player in the rapidly growing oncology diagnostics market and adding a new high-growth segment to its portfolio.
Abbott maintained a positive outlook for 2026, projecting full-year comparable sales growth of 6.5% to 7.5% and adjusted EPS of $5.38 to $5.58, including a modest dilution impact from the acquisition. The company also reported progress across its medical technology pipeline, including advancements in cardiovascular devices and diabetes management solutions, supporting expectations for accelerating growth through the year.
PRNewswire
